Search

Search Constraints

You searched for: Author/Creator Park-Simon, Tjoung-Won

Search Results

1. 2022-RA-835-ESGO AGO-OVAR 2.34/MIROVA: A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy. (20th October 2022)

2. A role for XRCC2 gene polymorphisms in breast cancer risk and survival. Issue 7 (31st May 2011)

3. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Issue 5 (May 2020)

4. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Issue 5 (May 2020)

5. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. (July 2021)

6. Clonal Hematopoiesis–Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer. (28th December 2021)

7. Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. (November 2020)

8. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). Issue 9 (12th April 2019)

9. Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Issue 1 (December 2016)

10. Incorporating progesterone receptor expression into the PREDICT breast prognostic model. (September 2022)